SPOTLIGHT: ZymoGenetics inks $198M deal

ZymoGenetics is pocketing a $30 million upfront payment from Bayer HealthCare for a global license to help sell the blood clotting drug rThrombin. An FDA approval would trigger another $40 million payday in a licensing deal valued at up to $198 million plus royalties. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.